Figure 4.

Effect of CB₂ agonists on TNF-α-induced human vascular smooth muscle cell proliferation. Panel (a) shows HCASMCs were treated as indicated and proliferation was determined by measuring the extent of BrdU incorporation using ELISA kit by absorbance at 450 nm. ^*P<0.05 vs control; ^#P<0.05 vs TNF-α; n=6. The concentration of TNF-α used in these experiments was 50 ng ml⁻¹. In panel (b) HCASMCs were treated as shown, and proliferation was determined by ELISA. The CB₂ agonists were used at concentration of 4 μM, while the antagonists were used at 1 μM, respectively. ^*P<0.05 vs control; ^#P<0.05 vs TNF-α; ^†P<0.05 vs TNF-α+HU-308/JWH-133, n=6.